Cargando…

Therapeutic Efficacy of Molecular Hydrogen: A New Mechanistic Insight

BACKGROUND: Molecular hydrogen (H(2)) is now recognized as a therapeutic gas for the treatment of numerous diseases including neurodegenerative diseases, metabolic disorders, and inflammatory diseases. Non-polar, neutral H(2) is assumed to have health benefits facilitated by its passive diffusion ac...

Descripción completa

Detalles Bibliográficos
Autor principal: Ishibashi, Toru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6806612/
https://www.ncbi.nlm.nih.gov/pubmed/31057105
http://dx.doi.org/10.2174/1381612825666190506123038
_version_ 1783461673461350400
author Ishibashi, Toru
author_facet Ishibashi, Toru
author_sort Ishibashi, Toru
collection PubMed
description BACKGROUND: Molecular hydrogen (H(2)) is now recognized as a therapeutic gas for the treatment of numerous diseases including neurodegenerative diseases, metabolic disorders, and inflammatory diseases. Non-polar, neutral H(2) is assumed to have health benefits facilitated by its passive diffusion across the human body immediately after administration and is considered a safe therapeutic inert gas that does not interfere with physiological enzymatic reactions. The effects of H(2) on mammalian cells are assumed to be based on non-enzymatic reactions with Reactive Oxygen Species (ROS) exhibiting extremely high reactivity. However, many reports on therapeutic applications of H(2) have the limitation to regard H2 only as a scavenger for the hydroxyl radical and peroxynitrite. METHODS: Apart from this proposed principle, a new possible mechanism of H(2) activation and consumption in mammalian cells is considered in this review, which is specifically focused on the mitochondrial complex I that has a close evolutionary relationship with energy-converting, membrane-bound [NiFe]-hydrogenases (MBH). Notably, the possibility that H2 may function as both electron and proton donor in the ubiquinone-binding chamber of complex I is discussed. RESULTS: H(2) is proposed to act as the rectifier of the mitochondrial electron flow in the disordered or pathological state when the accumulation of electrons leads to ROS production, specifically during the re-supply of O(2) after hypoxia in the mitochondria. CONCLUSION: Furthermore, H(2) is proposed to convert the quinone intermediates to the fully reduced ubiquinol, thereby increasing the antioxidant capacity of the quinone pool as well as preventing the generation of ROS.
format Online
Article
Text
id pubmed-6806612
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-68066122019-11-08 Therapeutic Efficacy of Molecular Hydrogen: A New Mechanistic Insight Ishibashi, Toru Curr Pharm Des Article BACKGROUND: Molecular hydrogen (H(2)) is now recognized as a therapeutic gas for the treatment of numerous diseases including neurodegenerative diseases, metabolic disorders, and inflammatory diseases. Non-polar, neutral H(2) is assumed to have health benefits facilitated by its passive diffusion across the human body immediately after administration and is considered a safe therapeutic inert gas that does not interfere with physiological enzymatic reactions. The effects of H(2) on mammalian cells are assumed to be based on non-enzymatic reactions with Reactive Oxygen Species (ROS) exhibiting extremely high reactivity. However, many reports on therapeutic applications of H(2) have the limitation to regard H2 only as a scavenger for the hydroxyl radical and peroxynitrite. METHODS: Apart from this proposed principle, a new possible mechanism of H(2) activation and consumption in mammalian cells is considered in this review, which is specifically focused on the mitochondrial complex I that has a close evolutionary relationship with energy-converting, membrane-bound [NiFe]-hydrogenases (MBH). Notably, the possibility that H2 may function as both electron and proton donor in the ubiquinone-binding chamber of complex I is discussed. RESULTS: H(2) is proposed to act as the rectifier of the mitochondrial electron flow in the disordered or pathological state when the accumulation of electrons leads to ROS production, specifically during the re-supply of O(2) after hypoxia in the mitochondria. CONCLUSION: Furthermore, H(2) is proposed to convert the quinone intermediates to the fully reduced ubiquinol, thereby increasing the antioxidant capacity of the quinone pool as well as preventing the generation of ROS. Bentham Science Publishers 2019-03 2019-03 /pmc/articles/PMC6806612/ /pubmed/31057105 http://dx.doi.org/10.2174/1381612825666190506123038 Text en © 2019 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Ishibashi, Toru
Therapeutic Efficacy of Molecular Hydrogen: A New Mechanistic Insight
title Therapeutic Efficacy of Molecular Hydrogen: A New Mechanistic Insight
title_full Therapeutic Efficacy of Molecular Hydrogen: A New Mechanistic Insight
title_fullStr Therapeutic Efficacy of Molecular Hydrogen: A New Mechanistic Insight
title_full_unstemmed Therapeutic Efficacy of Molecular Hydrogen: A New Mechanistic Insight
title_short Therapeutic Efficacy of Molecular Hydrogen: A New Mechanistic Insight
title_sort therapeutic efficacy of molecular hydrogen: a new mechanistic insight
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6806612/
https://www.ncbi.nlm.nih.gov/pubmed/31057105
http://dx.doi.org/10.2174/1381612825666190506123038
work_keys_str_mv AT ishibashitoru therapeuticefficacyofmolecularhydrogenanewmechanisticinsight